A pill that helps lower bad cholesterol even more in people who already take statins

Original Title

Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.

Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms

Summary

Some people have very high bad cholesterol because of their genes. Even when they take cholesterol pills like statins, their levels stay too high. This study tested a new pill called enlicitide to see if it helps lower cholesterol even more.

Sign up to see full results

Get access to research results, context, and detailed analysis.

Surprising Findings

Enlicitide significantly reduced lipoprotein(a) by 27.5% in just 24 weeks.

Lipoprotein(a) is a genetically driven risk factor that is notoriously resistant to most lipid-lowering therapies, including statins. Large reductions are rare and considered a major breakthrough.

Practical Takeaways

People with familial hypercholesterolemia who aren’t reaching cholesterol goals on statins may benefit from emerging oral PCSK9 inhibitors like enlicitide.

low confidence

Unlock Full Study Analysis

Sign up free to access quality scores, evidence strength analysis, and detailed methodology breakdowns.

47%
Moderate QualityOverall Score

Publication

Journal

JAMA

Year

2025

Authors

Christie M. Ballantyne, Laura A Gellis, J. Tardif, Puja Banka, A. Navar, E. A. Asprusten, Russell Scott, E. Stroes, Samar Froman, G. Mendizabal, Fan Wang, A. Catapano

Open Access
21 citations
Analysis v1